WO2005040097A1 - Resolution of 3-amino alkylnitriles - Google Patents

Resolution of 3-amino alkylnitriles Download PDF

Info

Publication number
WO2005040097A1
WO2005040097A1 PCT/IB2004/003395 IB2004003395W WO2005040097A1 WO 2005040097 A1 WO2005040097 A1 WO 2005040097A1 IB 2004003395 W IB2004003395 W IB 2004003395W WO 2005040097 A1 WO2005040097 A1 WO 2005040097A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetyl
amino
valine
isoleucine
alkylnitrile
Prior art date
Application number
PCT/IB2004/003395
Other languages
French (fr)
Inventor
Juan Carlos Colberg
Samuela Zambelli Franz
Riccardo Motterle
Mariano Stivanello
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to MXPA06004720A priority Critical patent/MXPA06004720A/en
Priority to AU2004283151A priority patent/AU2004283151A1/en
Priority to BRPI0415962-4A priority patent/BRPI0415962A/en
Priority to NZ546586A priority patent/NZ546586A/en
Priority to CA002543606A priority patent/CA2543606A1/en
Priority to JP2006537456A priority patent/JP2007509922A/en
Priority to EP04769657A priority patent/EP1689703A1/en
Publication of WO2005040097A1 publication Critical patent/WO2005040097A1/en
Priority to IL174840A priority patent/IL174840A0/en
Priority to NO20062372A priority patent/NO20062372L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • C07C253/34Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to a process for preparing optically active ⁇ - amino alkylnitriles, which are useful as building blocks in the synthesis of optically active ⁇ -amino acids and pharmaceutical drugs, via the resolution of racemic ⁇ -amino alkylnitriles using, as resolving agents, optically active N-acetyl-alpha-amino acids.
  • the present invention relates to chiral N-acetyl-alpha- amino acid salts of optically active ⁇ -amino alkylnitriles and also to a process for preparing optically active ⁇ -amino alkylnitriles by resolving racemic ⁇ -amino alkylnitriles using chiral N-acetyl-alpha-amino acids as resolving agents.
  • ⁇ -amino acids have been isolated in free form and show useful pharmacological properties.
  • ⁇ -amino acids can be cyclized to ⁇ - lactams, a well-known class of potential biologically active substances. These types of compounds are also excellent building blocks for the preparation of multiple natural products and have been shown to be useful tools in the synthesis of modified peptides with increased activity and in vivo stability.
  • Steer et al. in The Use of ⁇ -amino Acids in the Design of Protease and Peptidase Inhibitors, report that a peptidomimetic approach with significant potential has emerged in recent years that utilizes ⁇ -amino acids.
  • ⁇ -amino acids The one important feature of ⁇ -amino acids is reported to be their biological stability.
  • the biological stability is reported to be due to the fact that while ⁇ -amino acids, which have a similarity to ⁇ - amino acids in that they contain an amino terminus and a carboxyl terminus, also have two carbon atoms which separate these functional termini.
  • ⁇ -amino acids with a specific side chain can exist as the R or S isomers at either the ⁇ (C2) carbon or the ⁇ (C3) carbon resulting in a total of four possible isomers for any given side chain. This demonstrates that many more isomers are available in ⁇ -amino acids than is possible for the corresponding ⁇ -amino acids.
  • the present invention provides a compound of formula Ha or lib
  • R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L- aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N- acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L- serine, N-acetyl-L-th
  • Q is selected from the group consisting of N- acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N- acetyl-L-lysine and N-acetyl-L-valine.
  • Q is N-acetyl-L-isoleucine.
  • Q is N-acetyl-L- valine.
  • R is ethyl.
  • R is methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl, to the corresponding (R) or (S) isomer of formula Ha or lib
  • N-acetyl-L-amino acid of formula Q wherein Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N- acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L- glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N- acetyl-L-lysine, N-acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L- proline, N-acetyl-L-amino acid of formula Q wherein Q is N-acetyl-L-alanine, N-acetyl-L
  • Q is selected from the group consisting of N-acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N- acetyl-L-leucine, N-acetyl-L-lysine and N-acetyl-L-valine.
  • Q is N-acetyl-L-isoleucine.
  • Q is N-acetyl-L- valine.
  • R is ethyl.
  • a process for converting R or S 3-amino-(C 3 -C 7 )alkylnitrile to racemic 3-amino-(C 3 -C 7 )alkylnitrile comprising combining R or S 3-aminopentanenitrile with aqueous ammonia at a temperature that is in a range of from about 30°C to about 200°C.
  • the racemic amino(C 3 - C 7 )alkylnitrile is R-3-aminopentanenitrile.
  • R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl- L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N-acetyl-L- methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L-serine, N- acetyl-L-
  • solving has its conventional meaning, i.e., converting a racemic 3-amino alkylnitrile of formula I to a product (i.e. a composition)enriched in the corresponding (R) or (S) isomer.
  • An enriched composition is one that contains a higher abundance or proportion of one stereoisomer over the other.
  • an enriched composition generally contains a higher proportion of a desired stereoisomer (i.e. an enantiomer) relative to the racemate.
  • the amino-carbon bonds have their art-recognized stereochemical meanings. For example, in formula I above the straight-line amino-carbon bond represents the racemate.
  • ⁇ in formulas I, Ha and lib denotes a salt pair.
  • the salt formed between the optically active N-acetyl-alpha amino acid, Q, and either the (R)-stereoisomer or the (S)-stereoisomer of the ⁇ -amino alkylnitrile substrate has the formula Ha or lib
  • the particular salt formed depends, of course, on the stereochemistry of the particular N-acetyl-alpha amino acid used to resolve the ⁇ -amino alkylnitrile. If the desired stereoisomer is contained in the salt, the salt generally precipitates and can be isolated, for example by filtration. Q can then be displaced to yield the desired optically active ⁇ -amino alkylnitrile. If, on the other hand, the desired isomer is contained in the mother liquor, the mother liquor can be concentrated to yield the desired optically active ⁇ -amino alkylnitrile.
  • optically active N-acetyl-alpha-amino acids may be used to resolve racemic ⁇ -amino alkylnitriles of the formula I.
  • the racemic ⁇ -amino alkylnitrile is reacted with (also referred to herein as "treated") an N-acetyl alpha-amino acid stereoisomer to form either of the corresponding optically active salts of formula Ha and lib, in excellent enantiomeric purity and overall yield.
  • the salt of formula Ha or lib that is formed precipitates, leaving the remaining ⁇ -amino alkylnitrile stereoisomer dissolved in the mother liquor.
  • the salt can be isolated, for example by filtration, and Q can be displaced to yield the desired optically active ⁇ -amino alkylnitrile.
  • the mother liquor can be concentrated to yield the desired optically active ⁇ -amino alkylnitrile.
  • the mother liquor can first be extracted with a suitable (immiscible) extracting solvent, for example a solvent having a low boiling point, and then concentrated by evaporating off the low boiling solvent.
  • a specific exemplary embodiment of this invention relates to a process as described above, wherein L-N-acetylvaline is used as the resolving agent and an alcohol, for example ethanol, is employed as the solvent for the crystallization of the ⁇ -amino alkylnitrile-L-N-acetylvalinate salt.
  • an alcohol for example ethanol
  • the inventors determined that the above procedure may be used to prepare (R)-3- aminopentanitrile from the racemic mixture, using N-acetylamino acids. More specifically, L-N-acetylvaline is used as a resolving agent followed by free-basing the valinate salt using known art procedures.
  • Scheme 1 provides the preparation of the chiral (R) or (S) 3-amino alkylnitrile N-acetyl-alpha-aminoacid salt of formula lla or lib starting from an appropriate alkyl-2-enenitrile of formula III.
  • the alkyl-2-ene nitrile of formula III is reacted with aqueous ammonium hydroxide, preferably at a pressure of approximately 12 bar and a temperature of approximately 150°C to provide the racemic 3-amino alkyl of formula I.
  • the chiral 3-amino alkylnitrile N-acetyl-alpha- amino acid salt of formula lla or lib is then prepared by reacting the racemic 3- amino alkylnitrile of formula I with an appropriate chiral N-acetyl-alpha-amino acid Q preferably, in an alcoholic or aqueous/alcoholic solvent, at a temperature of about -20 ° to about 120 ° C.
  • the salt formation is most preferably conducted using ethanol/water as the solvent mixture and in a range of about 0.5 to about 1.1 moles of formula Q per mole of ⁇ -amino alkylnitrile of formula I.
  • the reaction may be carried out at temperatures ranging from about room temperature to about 80° C.
  • the reaction is preferably carried out at a temperature ranging from about 65°C to about 80°C.
  • the reaction is continued until a solution is obtained.
  • the mixture is then cooled, filtered and the desired isomer is isolated, for example by filtration if it separates from the mother liquor as the salt, or by evaporation if it remains in the mother liquor as the unprecipitated remaining ⁇ -amino alkylnitrile stereoisomer.
  • a preferred method for preparing the chiral 3-amino alkylnitrile N-acetyl- alpha-amino acid salt of formula lla or lib employs reacting 0.9 equivalents of an appropriate chiral N-acetyl-alpha-amino acid of formula Q with 1.0 equivalents of the racemic 3-amino alkylnitrile in aqueous ethanol. More particularly, the racemic 3-amino alkylnitrile of formula I is added to the chiral N-acetyl-alpha-amino acid Q in aqueous ethanol at approximately 65° to 70°C. The reaction mixture is then heated at reflux until a homogenous solution is obtained.
  • the reaction mixture is then cooled to approximately 60 ° C and maintained at this temperature for a minimum of 30 minutes.
  • the reaction mixture is then further cooled to 0 ° C and the chiral 3- amino-alkylnitrile-N-acetyl-alpha-aminoacid salt of formula I, which has precipitated, is separated and collected by filtration.
  • the filtrate will be enriched in the remaining steroisomer. If the filtrate is enriched in the undesired isomer, it can be treated as described above to racemize the steroisomer and then recycled through the resolution procedure. If it contains the desired stereoisomer, it can be concentrated as by evaporation to recover the isomer, optionally with an intermediate extraction step.
  • the resulting racemic mixture can then be resolved according to known procedures disclosed herein, that is, the racemic mixture can be reacted with an N-acetylamino acid defined herein as Q to produce the enantiomerically enriched salt of formula lla or lib in accordance with the conditions described above in Scheme 1.
  • N-acetyl-L-valine (145.4 g, 0.91 mol eq) is combined with ethanol (1425 mL) and water (75 mL) in a vessel equipped with agitation and condenser.
  • the mixture is heated to 65°-70°C followed by the addition (with a syringe) of racemic 3- aminopentanenitrile.
  • the mixture is heated at reflux until a complete solution is obtained.
  • the mixture is cooled to 60°C and held at this temperature for a minimum of 30 minutes.
  • the mixture is cooled to 0°C and the salt is isolated by filtration.
  • Example III Resolution of 3-aminopentanenitrile with N-acetyl-L- isoleucine.
  • N-acetyl-L-isoleucine (157 g, 0.91 mol eq) is combined with ethanol (250 mL) and water (75 mL) in a vessel equipped with agitation and condenser. The mixture is heated to 65°-70°C followed by the addition of racemic 3- aminopentanenitrile. The mixture is heated at reflux until a complete solution is obtained. The mixture is cooled to 60°C and held at this temperature for a minimum of 30 minutes. The mixture is cooled to 0°C and the salt isolated by filtration (70% yield based in a maximum of 50% and 99.8% ee).
  • Example IV Racemization of R-3-aminopentanenitrile.
  • R-3-aminopentanenitrile (197 g, 2.1 mol eq) is combined with ammonia 30% water solution (930 mL, 14.7 mol eq.)in a suitable pressure rated vessel and the mixture is heated to 130°C. After 6 hours the mixture is cooled and analyzed for complete racemization. The mixture is concentrated under vacuum (15 mmHg, 88 C) to 300 mL. The crude product is distilled under vacuum for further purification to obtain 160g of the racemic mixture (77% yield, 95% GC pure, 50/50% R/S).
  • Example V Free basing of 3-aminopentanenitrile N-acetyl-L-valine salt.
  • 3-aminopentanenitrile N-acetyl-L-valine salt (230 g) is combined with dichloromethane (713 mL).
  • dichloromethane 713 mL
  • a sodium hydroxide aqueous solution (98 mL, 30% w/w) and the mixture stirred at 20°-25°C for 1 hour.
  • the lower organic phase is separated and the upper aqueous phase washed with additional dichloromethane (2 x 180 mL).
  • the organic layers are combined, concentrated and the optically active 3-aminopentanenitrile isolated by distillation (80% yield, 99.8% ee)
  • Example VI Preparation of 3-Amino-pentanenitrile L-Acetyl-L-valine salt
  • N-acetyl-L-valine 145.4 g
  • denaturated ethanol 1425 ml
  • water 75 ml
  • the mixture was heated under stirring to 65-70°C and150 g of 3-aminopentanenitrile were added.
  • the solution was heated to reflux (about 75°C) until obtaining a complete clear solution that was then slowly cooled to 65°C.
  • Example VII Preparation of 3-Amino-pentanenitrile L-Acetyl-L-valine salt
  • N-acetyl-L-valine 200.0 g
  • denaturated ethanol denatured with about 5% methanol and 3% cyclohexane
  • water 100 ml
  • 3-aminopentanenitrile 206.4 g
  • the solution was heated to reflux (about 75°C) until obtaining a complete clear solution which was then slowly cooled to 65°C.
  • the precipitate salt was filtered and washed with denaturated ethanol (3 X 100 ml) and dried in an vacuum try-drier at 40° C/10 mbar until constant weight, obtaining 3-amino-pentanenitrile-L- acetyl-L-valine salt (228.7 g), white crystalline solid (yield 84.8%) having optical purity 97.7%.
  • Example VIII Preparation of 3-Amino-pentanenitrile L-acetyl-L-isoleucine salt
  • 3-aminopentanenitrile 5 g
  • N-acetyl-L-isoleucine 8.8 g
  • denaturated ethanol denatured with about 5% methanol and 3% cyclohexane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to chiral N-acetyl-alpha-amino acid salts of optically active β-amino alkylnitriles, and also to a process for preparing optically active β-amino alkylnitriles by resolving racemic β-amino alkylnitriles using chiral N-acetyl-alpha-amino acids as resolving agent.

Description

RESOLUTION OF 3-AMINO ALKYLNITRILES
FIELD OF THE INVENTION The present invention relates to a process for preparing optically active β- amino alkylnitriles, which are useful as building blocks in the synthesis of optically active β-amino acids and pharmaceutical drugs, via the resolution of racemic β-amino alkylnitriles using, as resolving agents, optically active N-acetyl-alpha-amino acids. More specifically, the present invention relates to chiral N-acetyl-alpha- amino acid salts of optically active β-amino alkylnitriles and also to a process for preparing optically active β-amino alkylnitriles by resolving racemic β-amino alkylnitriles using chiral N-acetyl-alpha-amino acids as resolving agents.
BACKGROUND OF THE INVENTION β-amino acids have been isolated in free form and show useful pharmacological properties. For example, β-amino acids can be cyclized to β- lactams, a well-known class of potential biologically active substances. These types of compounds are also excellent building blocks for the preparation of multiple natural products and have been shown to be useful tools in the synthesis of modified peptides with increased activity and in vivo stability. Steer et al., in The Use of β-amino Acids in the Design of Protease and Peptidase Inhibitors, report that a peptidomimetic approach with significant potential has emerged in recent years that utilizes β-amino acids. The one important feature of β-amino acids is reported to be their biological stability. The biological stability is reported to be due to the fact that while β-amino acids, which have a similarity to α- amino acids in that they contain an amino terminus and a carboxyl terminus, also have two carbon atoms which separate these functional termini. As such, β-amino acids with a specific side chain can exist as the R or S isomers at either the α (C2) carbon or the β (C3) carbon resulting in a total of four possible isomers for any given side chain. This demonstrates that many more isomers are available in β-amino acids than is possible for the corresponding α-amino acids. Steer, David L.; Lew, Rebecca A.; Perlmutter, Patrick; Smith, A. Ian; Aguilar, Marie-Isabel; Letters in Peptide Science (2002), Volume Date 2001 , 8(3-5), 241-246. ln β-Amino Acids: Versatile Peptidomimetics, Steer et al. review the use of β-amino acids in the design and synthesis of biologically active peptide analogues. They disclose that β-amino acids in the design of bioactive peptide analogues are rapidly expanding. The incorporation of β-amino acids is noted to be successful in creating peptidomimetics that not only have potent biological activity, but that are also resistant to proteolysis. Steer, David L.; Lew, Rebecca A.; Perlmutter, Patrick; Smith, A. Ian; Aguilar, Marie-Isabel. Current Medicinal Chemistry (2002), 9(8), 811-822. Several methods for the preparation of enantiopure β-amino acids and their derivatives already exist. Among these methods, the conjugate addition of amines to unsaturated nitriles or esters followed by hydrolysis is useful due to raw material availability. Although this addition reaction results in high yield processes for the formation of racemic β-amino acids, most attempts to control the stereochemistry of the chiral center result in low yields and poor enantiomeric excess. Considering the low cost of preparing racemic mixtures of β-amino alkylnitriles, resolution of these racemic substrates presents an excellent opportunity to develop a low cost process for the synthesis of optically active β- amino alkylnitriles and their corresponding β-amino acids as building blocks for making useful pharmaceutical compounds. However, little if any effort in this area appears in the scientific literature. Thus, there exists a need in the art for an efficient, low cost process for resolving racemic β-amino alkylnitriles. SUMMARY OF THE INVENTION According to one aspect, the present invention provides a compound of formula Ha or lib
Figure imgf000003_0001
Ha or lib
wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L- aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N- acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L- serine, N-acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L-tyrosine, N-acetyl-L- valine, N-acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D-asparagine, N-acetyl-D- aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N-acetyl-D-glutamic acid, N-acetyl-D-histidine, N-acetyl-D-isoleucine, N-acetyl-D-leucine, N-acetyl-D-lysine, N-acetyl-D-methionine, N-acetyl-D-phenylalamine, N-acetyl-D-proline, N-acetyl-D- serine, N-acetyl-D-threonine, N-acetyl-D-tryptophan, N-acetyl-D-tyrosine, or N- acetyl-D-valine. In a preferred embodiment, Q is selected from the group consisting of N- acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N- acetyl-L-lysine and N-acetyl-L-valine. In another preferred embodiment, Q is N-acetyl-L-isoleucine. In still another preferred embodiment, Q is N-acetyl-L- valine. According to another preferred embodiment R is ethyl. According to another aspect of the present invention, there is provided a process for converting a racemic 3-amino-(C3-C7)alkylnitrile of formula I
Figure imgf000004_0001
wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl, to the corresponding (R) or (S) isomer of formula Ha or lib
Figure imgf000004_0002
comprising combining, in a solvent, the racemic 3-amino(C3-C7)alkylnitrile of formula I with an N-acetyl-L-amino acid of formula Q wherein Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N- acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L- glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N- acetyl-L-lysine, N-acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L- proline, N-acetyl-L-serine, N-acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L- tyrosine, N-acetyl-L-valine, N-acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D- asparagine, N-acetyl-D-aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N- acetyl-D-glutamic acid, N-acetyl-D-histidine, N-acetyl-D-isoleucine, N-acetyl-D- leucine, N-acetyl-D-lysine, N-acetyl-D-methionine, N-acetyl-D-phenylalamine, N- acetyl-D-proline, N-acetyl-D-serine, N-acetyl-D-threonine, N-acetyl-D-tryptophan, N- acetyl-D-tyrosine, or N-acetyl-D-valine in a solvent wherein the solvent is selected from the group consisting of ethanol, n-propanol, isopropanol, n-butanol, t-butanol, methanol and water or a mixture thereof. In a preferred embodiment of the process, Q is selected from the group consisting of N-acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N- acetyl-L-leucine, N-acetyl-L-lysine and N-acetyl-L-valine. In another preferred embodiment of the process, Q is N-acetyl-L-isoleucine. In another preferred embodiment of the process, Q is N-acetyl-L- valine. In another preferred embodiment of the process, R is ethyl. According to another aspect of the invention, there is provided a process for converting R or S 3-amino-(C3-C7)alkylnitrile to racemic 3-amino-(C3-C7)alkylnitrile comprising combining R or S 3-aminopentanenitrile with aqueous ammonia at a temperature that is in a range of from about 30°C to about 200°C. According to another aspect of the invention, the racemic amino(C3- C7)alkylnitrile is R-3-aminopentanenitrile. According to another aspect of the invention, there is provided a composition enriched in the compound of formula lla or lib as described above. According to another aspect of the invention, there is provided a compound of formula 1
Figure imgf000005_0001
wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl- L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N-acetyl-L- methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L-serine, N- acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L-tyrosine, N-acetyl-L-valine, N- acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D-asparagine, N-acetyl-D-aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N-acetyl-D-glutamic acid, N-acetyl- D-histidine, N-acetyl-D-isoleucine, N-acetyl-D-leucine, N-acetyl-D-lysine, N-acetyl- D-methionine, N-acetyl-D-phenylalamine, N-acetyl-D-proline, N-acetyl-D-serine, N- acetyl-D-threonine, N-acetyl-D-tryptophan, N-acetyl-D-tyrosine, or N-acetyl-D- valine. The term "resolving" as employed herein has its conventional meaning, i.e., converting a racemic 3-amino alkylnitrile of formula I to a product (i.e. a composition)enriched in the corresponding (R) or (S) isomer. An enriched composition is one that contains a higher abundance or proportion of one stereoisomer over the other. Thus, an enriched composition generally contains a higher proportion of a desired stereoisomer (i.e. an enantiomer) relative to the racemate. In the formulas herein, and unless otherwise indicated, the amino-carbon bonds have their art-recognized stereochemical meanings. For example, in formula I above the straight-line amino-carbon bond represents the racemate. A thickened amino-carbon bond, as in formula Ha (see below), is above the plane of the page. A dashed or dotted amino-carbon bond, as in formula lib, is below the plane of the page. Those skilled in the art will readily appreciate that the symbol in formulas I, Ha and lib denotes a salt pair. The salt formed between the optically active N-acetyl-alpha amino acid, Q, and either the (R)-stereoisomer or the (S)-stereoisomer of the β-amino alkylnitrile substrate has the formula Ha or lib
Figure imgf000006_0001
wherein Q, R, and the amino-carbon bonds each have the meaning given above. The particular salt formed depends, of course, on the stereochemistry of the particular N-acetyl-alpha amino acid used to resolve the β-amino alkylnitrile. If the desired stereoisomer is contained in the salt, the salt generally precipitates and can be isolated, for example by filtration. Q can then be displaced to yield the desired optically active β-amino alkylnitrile. If, on the other hand, the desired isomer is contained in the mother liquor, the mother liquor can be concentrated to yield the desired optically active β-amino alkylnitrile. The inventors determined that optically active N-acetyl-alpha-amino acids, defined herein as Q, may be used to resolve racemic β-amino alkylnitriles of the formula I. The racemic β-amino alkylnitrile is reacted with (also referred to herein as "treated") an N-acetyl alpha-amino acid stereoisomer to form either of the corresponding optically active salts of formula Ha and lib, in excellent enantiomeric purity and overall yield. In general, the salt of formula Ha or lib that is formed precipitates, leaving the remaining β-amino alkylnitrile stereoisomer dissolved in the mother liquor. If the desired stereoisomer is contained in the salt, the salt can be isolated, for example by filtration, and Q can be displaced to yield the desired optically active β-amino alkylnitrile. If, on the other hand, the desired isomer is contained in the mother liquor, the mother liquor can be concentrated to yield the desired optically active β-amino alkylnitrile. Optionally, the mother liquor can first be extracted with a suitable (immiscible) extracting solvent, for example a solvent having a low boiling point, and then concentrated by evaporating off the low boiling solvent. A specific exemplary embodiment of this invention relates to a process as described above, wherein L-N-acetylvaline is used as the resolving agent and an alcohol, for example ethanol, is employed as the solvent for the crystallization of the β-amino alkylnitrile-L-N-acetylvalinate salt. In another specific embodiment, the inventors determined that the above procedure may be used to prepare (R)-3- aminopentanitrile from the racemic mixture, using N-acetylamino acids. More specifically, L-N-acetylvaline is used as a resolving agent followed by free-basing the valinate salt using known art procedures. DETAILED DESCRIPTION OF THE INVENTION It has been discovered that the resolution of a racemic 3-amino alkylnitrile by treatment with L-N-acetyl amino acids can provide a high yielding resolution reaction with very high selectivity. In addition, it has been discovered that this approach provides a low cost/high efficiency procedure for synthesizing a compound of interest such as R-3-aminopentanenitrile. Certain processes for the manufacture of optically active β-amino alkylnitriles are provided as further features of the invention and are described below and in the experimental section. All starting materials are commercially available; moreover, their syntheses will be readily apparent to a skilled individual. See, for example Synthesis of N- acetyl Amino acids, Marshall, J.J. AM. Chem. Soc. 1956, 78, 4636.
SCHEME 1
Figure imgf000008_0001
(R S isomers)
Figure imgf000008_0002
lib
In the above, R and Q are as previously defined. Scheme 1 , as depicted above, provides the preparation of the chiral (R) or (S) 3-amino alkylnitrile N-acetyl-alpha-aminoacid salt of formula lla or lib starting from an appropriate alkyl-2-enenitrile of formula III. The alkyl-2-ene nitrile of formula III is reacted with aqueous ammonium hydroxide, preferably at a pressure of approximately 12 bar and a temperature of approximately 150°C to provide the racemic 3-amino alkyl of formula I. The chiral 3-amino alkylnitrile N-acetyl-alpha- amino acid salt of formula lla or lib is then prepared by reacting the racemic 3- amino alkylnitrile of formula I with an appropriate chiral N-acetyl-alpha-amino acid Q preferably, in an alcoholic or aqueous/alcoholic solvent, at a temperature of about -20° to about 120°C. The salt formation is most preferably conducted using ethanol/water as the solvent mixture and in a range of about 0.5 to about 1.1 moles of formula Q per mole of β-amino alkylnitrile of formula I. The reaction may be carried out at temperatures ranging from about room temperature to about 80° C. The reaction is preferably carried out at a temperature ranging from about 65°C to about 80°C. The reaction is continued until a solution is obtained. The mixture is then cooled, filtered and the desired isomer is isolated, for example by filtration if it separates from the mother liquor as the salt, or by evaporation if it remains in the mother liquor as the unprecipitated remaining β-amino alkylnitrile stereoisomer. A preferred method for preparing the chiral 3-amino alkylnitrile N-acetyl- alpha-amino acid salt of formula lla or lib employs reacting 0.9 equivalents of an appropriate chiral N-acetyl-alpha-amino acid of formula Q with 1.0 equivalents of the racemic 3-amino alkylnitrile in aqueous ethanol. More particularly, the racemic 3-amino alkylnitrile of formula I is added to the chiral N-acetyl-alpha-amino acid Q in aqueous ethanol at approximately 65° to 70°C. The reaction mixture is then heated at reflux until a homogenous solution is obtained. The reaction mixture is then cooled to approximately 60°C and maintained at this temperature for a minimum of 30 minutes. The reaction mixture is then further cooled to 0°C and the chiral 3- amino-alkylnitrile-N-acetyl-alpha-aminoacid salt of formula I, which has precipitated, is separated and collected by filtration. The filtrate will be enriched in the remaining steroisomer. If the filtrate is enriched in the undesired isomer, it can be treated as described above to racemize the steroisomer and then recycled through the resolution procedure. If it contains the desired stereoisomer, it can be concentrated as by evaporation to recover the isomer, optionally with an intermediate extraction step. Those skilled in the art will readily appreciate that this procedure is generally applicable to any of the β-amino alkylnitriles useful in this invention, realizing that adjustments to the solvent (or solvent system if a mixture is used), temperature and particular chiral N-acetyl amino acid may be required to optimize yield. As previously noted, to maximize atom utilization the invention provides a process to racemize the undesired isomer as shown in Scheme 2. The chiral 3- amino(C3-C7)alkylnitrile is reacted with aqueous ammonium hydroxide at about 12 bar at approximately 120°C to 150"C for a period of 2 to 24 hours. The reaction mixture is then concentrated in vacuo and the resulting crude racemic 3-amino(C3- C7)alkylnitrile can be further isolated by vacuum distillation. SCHEME 2
Figure imgf000010_0001
(R or S isomer)
Figure imgf000010_0002
The resulting racemic mixture can then be resolved according to known procedures disclosed herein, that is, the racemic mixture can be reacted with an N-acetylamino acid defined herein as Q to produce the enantiomerically enriched salt of formula lla or lib in accordance with the conditions described above in Scheme 1.
EXAMPLES Example I. Synthesis of N-acetyl-L-valine. L-Valine (200 g, 1.7 mol eq) is dissolved in water (500 mL) followed by the addition of NaOH (30%, 170 mL).The mixture is cooled to 0°-5°C followed by the addition of acetic anhydride (32 ml, 1.4 eq.). Sodium hydroxide (30%, 34 mL) is added while keeping the temperature at 0°-5°C. Acetic anhydride and 30% NaOH alternate additions are repeated six time while keeping the temperature (acetic anhydride, 6 x 32 mL; 30% NaOH 6 x 34 mL). After all the additions are completed, the mixture is stirred for an additional two hours at 0°C. Hydrochloric acid (32%, 380 mL) is added to lower the pH below 3 while keeping the temperature at 0°C. The resulting slurry is granulated for 12 hours, filter and the cake washed with HCI (0.1 N, 100 mL). The wet N-acetyl-L-valine was dried to produce 233 g (86% yield).
Example II. Resolution of 3-aminopentanenitrile with N-acetyl-L-valine.
N-acetyl-L-valine (145.4 g, 0.91 mol eq) is combined with ethanol (1425 mL) and water (75 mL) in a vessel equipped with agitation and condenser. The mixture is heated to 65°-70°C followed by the addition (with a syringe) of racemic 3- aminopentanenitrile. The mixture is heated at reflux until a complete solution is obtained. The mixture is cooled to 60°C and held at this temperature for a minimum of 30 minutes. The mixture is cooled to 0°C and the salt is isolated by filtration.
Example III. Resolution of 3-aminopentanenitrile with N-acetyl-L- isoleucine. N-acetyl-L-isoleucine (157 g, 0.91 mol eq) is combined with ethanol (250 mL) and water (75 mL) in a vessel equipped with agitation and condenser. The mixture is heated to 65°-70°C followed by the addition of racemic 3- aminopentanenitrile. The mixture is heated at reflux until a complete solution is obtained. The mixture is cooled to 60°C and held at this temperature for a minimum of 30 minutes. The mixture is cooled to 0°C and the salt isolated by filtration (70% yield based in a maximum of 50% and 99.8% ee).
Example IV. Racemization of R-3-aminopentanenitrile. R-3-aminopentanenitrile (197 g, 2.1 mol eq) is combined with ammonia 30% water solution (930 mL, 14.7 mol eq.)in a suitable pressure rated vessel and the mixture is heated to 130°C. After 6 hours the mixture is cooled and analyzed for complete racemization. The mixture is concentrated under vacuum (15 mmHg, 88 C) to 300 mL. The crude product is distilled under vacuum for further purification to obtain 160g of the racemic mixture (77% yield, 95% GC pure, 50/50% R/S).
Example V. Free basing of 3-aminopentanenitrile N-acetyl-L-valine salt. 3-aminopentanenitrile N-acetyl-L-valine salt (230 g) is combined with dichloromethane (713 mL). To the mixture is added a sodium hydroxide aqueous solution (98 mL, 30% w/w) and the mixture stirred at 20°-25°C for 1 hour. The lower organic phase is separated and the upper aqueous phase washed with additional dichloromethane (2 x 180 mL). The organic layers are combined, concentrated and the optically active 3-aminopentanenitrile isolated by distillation (80% yield, 99.8% ee)
Example VI. Preparation of 3-Amino-pentanenitrile L-Acetyl-L-valine salt A 3 I flask equipped with mechanical stirrer, thermometer, dropping funnel, oil bath, was charged with N-acetyl-L-valine (145.4 g), denaturated ethanol (denatured with about 5% methanol and 3% cyclohexane) (1425 ml) and water (75 ml). The mixture was heated under stirring to 65-70°C and150 g of 3-aminopentanenitrile were added. The solution was heated to reflux (about 75°C) until obtaining a complete clear solution that was then slowly cooled to 65°C. Always under stirring the mixture was seeded with some diasteromerically pure 3-amino-pentanenitrile -L-acetyl-L- valine salt and stirred at 60°C for 1 hour. The thick suspension was then cooled to 0°C over a period of 3 hours and stirred at 0°C for 2 hours. The obtained salt was filtered and washed with 2 X 75 ml of ethanol. The optical purity of the wet product was 89.8% (A%). The wet salt was charged in a 2 I flask with standard equipment and 900 ml of denaturated ethanol were added. The suspension was heated to reflux, stirred for 1 hour at reflux temperature and then cooled to RT over a period of 2 hours. After 2 more hours of stirring at RT, the obtained salt was filtered and washed with 2 X 150 ml of denaturated ethanol. The product was dried at 40°C obtaining 118,3 g of 3-aminopentanenitrile -L-acetyl-L-valine salt, white crystalline solid (optical purity: 99,8% R; yield: 60% of theoretical).
Example VII. Preparation of 3-Amino-pentanenitrile L-Acetyl-L-valine salt A 3 I flask equipped with mechanical stirrer, thermometer, dropping funnel, oil bath, was charged with N-acetyl-L-valine (200.0 g) denaturated ethanol (denatured with about 5% methanol and 3% cyclohexane) (2000 ml) and water (100 ml). The mixture was heated under stirring to 65-70°C and 3-aminopentanenitrile (206.4 g) was added within 30 min. The solution was heated to reflux (about 75°C) until obtaining a complete clear solution which was then slowly cooled to 65°C. Always under stirring the mixture was seeded with some diasteromerically pure 3-amino- pentanenitrile-L-acetyl-L-valine salt and stirred at 60°C for 1 hour. The thick suspension was then slowly cooled to 20°C over a period of 3 hours and stirred at 20°C for 18 hours (overnight). The suspension was hence cooled to 5° C and stirred 3 hours. The precipitate salt was filtered and washed with denaturated ethanol (3 X 100 ml) and dried in an vacuum try-drier at 40° C/10 mbar until constant weight, obtaining 3-amino-pentanenitrile-L- acetyl-L-valine salt (228.7 g), white crystalline solid (yield 84.8%) having optical purity 97.7%.
Example VIII. Preparation of 3-Amino-pentanenitrile L-acetyl-L-isoleucine salt A 250 ml flask equipped with mechanical stirrer, thermometer, dropping funnel, oil bath, was charged with 3-aminopentanenitrile (5 g), N-acetyl-L-isoleucine (8.8 g), and of denaturated ethanol (denatured with about 5% methanol and 3% cyclohexane) (97 ml). The solution was heated to reflux until obtaining a complete clear solution which was then slowly cooled to 68°C. Always under stirring the mixture was seeded with some diasteromerically enriched 3-amino-pentanenitrile-L- acetyl-L-isoleucine salt and stirred at 65-70°C for 2 hour. The thick suspension was then cooled slowly to RT. The obtained salt was filtered and washed with ethanol. The product was dried at 50°C obtaining 3-amino-pentanenitrile -L-Acetyl-L- isoleucine salt (7.3 g), white crystalline solid (optical purity: 76% R; yield: 112% of theoretical). The obtained salt was charged in a 250 ml flask with standard equipment and methyl ethyl ketone (73 ml) was added. The suspension was heated to reflux, stirred for 1 hour at reflux temperature and then slowly cooled to 60°C The obtained salt was filtered and washed with methyl ethyl ketone. The product was dried at 50°C obtaining 3-amino-pentanenitrile-L- Acetylisoleucine salt (5.2 g), white crystalline solid (optical purity: 98.2% R; yield: 71.9% of theoretical).
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application for all purposes. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Claims

What is claimed is:
1. A compound of formula lla or lib
Figure imgf000014_0001
lla or lib wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl- L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N-acetyl-L- methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L-serine, N- acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L-tyrosine, N-acetyl-L-valine, N- acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D-asparagine, N-acetyl-D-aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N-acetyl-D-glutamic acid, N-acetyl- D-histidine, N-acetyl-D-isoleucine, N-acetyl-D-leucine, N-acetyl-D-lysine, N-acetyl- D-methionine, N-acetyl-D-phenylalamine, N-acetyl-D-proline, N-acetyl-D-serine, N- acetyl-D-threonine, N-acetyl-D-tryptophan, N-acetyl-D-tyrosine, or N-acetyl-D- valine.
2. The compound according to claim 1 wherein Q is selected from the group consisting of N-acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N- acetyl-L-leucine, N-acetyl-L-lysine and N-acetyl-L-valine.
3. The compound according to claim 2 wherein Q is N-acetyl-L-isoleucine.
4. The compound according to claim 2 wherein Q is N-acetyl-L- valine.
5. The compound according to any of claims 1-4 wherein R is ethyl.
6. A process for converting a racemic 3-amino-(C3-C7)alkylnitrile of formula I
Figure imgf000015_0001
wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl, to the corresponding (R) or (S) isomer of formula lla or lib
Figure imgf000015_0002
comprising combining, in a solvent, the racemic 3-amino(C3-C7)alkylnitrile of formula I with an N-acetyl-L-amino acid of formula Q
wherein Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N- acetyl-L-aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L- glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N- acetyl-L-lysine, N-acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L- proline, N-acetyl-L-serine, N-acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L- tyrosine, N-acetyl-L-valine, N-acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D- asparagine, N-acetyl-D-aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N- acetyl-D-glutamic acid, N-acetyl-D-histidine, N-acetyl-D-isoleucine, N-acetyl-D- leucine, N-acetyl-D-lysine, N-acetyl-D-methionine, N-acetyl-D-phenylalamine, N- acetyl-D-proline, N-acetyl-D-serine, N-acetyl-D-threonine, N-acetyl-D-tryptophan, N- acetyl-D-tyrosine, or N-acetyl-D-valine, wherein the solvent is selected from the group consisting of ethanol, n-propanol, isopropanol, n-butanol, t-butanol, methanol and water or a mixture thereof.
7. The process according to claim 6 wherein Q is selected from the group consisting of N-acetyl-L-alanine, N-acetyl-L-cysteine, N-acetyl-L-isoleucine, N- acetyl-L-leucine, N-acetyl-L-lysine and N-acetyl-L-valine.
8. The process according to claim 7 wherein Q is N-acetyl-L-isoleucine.
9. The process according to claim 7 wherein Q is N-acetyl-L- valine.
10. The process according to any of claims 6-9 wherein R is ethyl.
11. A process for converting R or S 3-amino-(C3-C7)alkylnitrile to racemic 3- amino-(C3-C7)alkylnitrile comprising combining R or S 3-aminopentanenitrile with aqueous ammonia at a temperature that is in a range of from about 30°C to about 200°C.
12. The process according to claim 11 wherein the racemic amino(C3- C7)alkylnitrile is R-3-aminopentanenitrile.
13. A composition enriched in a compound according to any of claims 1 through 4.
14. A compound of formula I
Figure imgf000016_0001
wherein R is methyl, ethyl, n-propyl, isopropyl, n-butyl, or isobutyl and Q is N-acetyl-L-alanine, N-acetyl-L-arginine, N-acetyl-L-asparagine, N-acetyl-L- aspartic acid, N-acetyl-L-cysteine, N-acetyl-L-glutamine, N-acetyl-L-glutamic acid, N-acetyl-L-histidine, N-acetyl-L-isoleucine, N-acetyl-L-leucine, N-acetyl-L-lysine, N- acetyl-L-methionine, N-acetyl-L-phenylalamine, N-acetyl-L-proline, N-acetyl-L- serine, N-acetyl-L-threonine, N-acetyl-L-tryptophan, N-acetyl-L-tyrosine, N-acetyl-L- valine, N-acetyl-D-alanine, N-acetyl-D-arginine, N-acetyl-D-asparagine, N-acetyl-D- aspartic acid, N-acetyl-D-cysteine, N-acetyl-D-glutamine, N-acetyl-D-glutamic acid, N-acetyl-D-histidine, N-acetyl-D-isoleucine, N-acetyl-D-leucine, N-acetyl-D-lysine, N-acetyl-D-methionine, N-acetyl-D-phenylalamine, N-acetyl-D-proline, N-acetyl-D- serine, N-acetyl-D-threonine, N-acetyl-D-tryptophan, N-acetyl-D-tyrosine, or N- acetyl-D-valine.
PCT/IB2004/003395 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles WO2005040097A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA06004720A MXPA06004720A (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles.
AU2004283151A AU2004283151A1 (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles
BRPI0415962-4A BRPI0415962A (en) 2003-10-28 2004-10-18 3-amino alkylnitrile resolution
NZ546586A NZ546586A (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles
CA002543606A CA2543606A1 (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles
JP2006537456A JP2007509922A (en) 2003-10-28 2004-10-18 Optical resolution of 3-amino alkyl nitrile
EP04769657A EP1689703A1 (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles
IL174840A IL174840A0 (en) 2003-10-28 2006-04-06 Resolution of 3-amino alkynitriles
NO20062372A NO20062372L (en) 2003-10-28 2006-05-24 Reading 3-aminoalkyl nitriles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51516003P 2003-10-28 2003-10-28
US60/515,160 2003-10-28

Publications (1)

Publication Number Publication Date
WO2005040097A1 true WO2005040097A1 (en) 2005-05-06

Family

ID=34520245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003395 WO2005040097A1 (en) 2003-10-28 2004-10-18 Resolution of 3-amino alkylnitriles

Country Status (17)

Country Link
US (1) US7026345B2 (en)
EP (1) EP1689703A1 (en)
JP (1) JP2007509922A (en)
KR (1) KR20060079252A (en)
CN (1) CN1874992A (en)
AR (1) AR046207A1 (en)
AU (1) AU2004283151A1 (en)
BR (1) BRPI0415962A (en)
CA (1) CA2543606A1 (en)
CO (1) CO5690565A2 (en)
IL (1) IL174840A0 (en)
MX (1) MXPA06004720A (en)
NO (1) NO20062372L (en)
NZ (1) NZ546586A (en)
RU (1) RU2309145C1 (en)
WO (1) WO2005040097A1 (en)
ZA (1) ZA200603356B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919200A1 (en) * 2007-07-27 2009-01-30 Novasep Process of continuous crystallization of a mixture for separation of diastereoisomer salts in various fields of chemistry, comprises injecting the mixture and the resolution agent in the reactor under continuous agitation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106905100B (en) * 2017-04-06 2022-07-15 联化科技(台州)有限公司 Resolution method of chiral amine compound and intermediate thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683324A (en) * 1982-05-25 1987-07-28 American Cyanamid Company Process for the resolution of certain racemic amino nitriles
WO2004002924A1 (en) * 2002-06-28 2004-01-08 Pcbu Services, Inc. Preparation of chiral amino-nitriles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610874B2 (en) 2001-09-28 2003-08-26 Pcbu Services, Inc. Processes and compositions for the production of chiral amino-nitriles
DE10249339A1 (en) 2002-10-22 2004-05-13 Bayer Ag Process for the resolution of 3-aminopentanenitrile
JP2004238322A (en) 2003-02-05 2004-08-26 Sumika Fine Chemicals Co Ltd Method for producing (r)-3-aminopentanenitrile methanesulfonic acid salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683324A (en) * 1982-05-25 1987-07-28 American Cyanamid Company Process for the resolution of certain racemic amino nitriles
WO2004002924A1 (en) * 2002-06-28 2004-01-08 Pcbu Services, Inc. Preparation of chiral amino-nitriles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919200A1 (en) * 2007-07-27 2009-01-30 Novasep Process of continuous crystallization of a mixture for separation of diastereoisomer salts in various fields of chemistry, comprises injecting the mixture and the resolution agent in the reactor under continuous agitation
WO2009047408A1 (en) * 2007-07-27 2009-04-16 Novasep Continuous crystallisation method

Also Published As

Publication number Publication date
AR046207A1 (en) 2005-11-30
CA2543606A1 (en) 2005-05-06
US7026345B2 (en) 2006-04-11
JP2007509922A (en) 2007-04-19
RU2309145C1 (en) 2007-10-27
NZ546586A (en) 2008-10-31
NO20062372L (en) 2006-05-24
KR20060079252A (en) 2006-07-05
MXPA06004720A (en) 2006-07-05
BRPI0415962A (en) 2007-01-23
CO5690565A2 (en) 2006-10-31
AU2004283151A1 (en) 2005-05-06
IL174840A0 (en) 2006-08-20
EP1689703A1 (en) 2006-08-16
CN1874992A (en) 2006-12-06
US20050107453A1 (en) 2005-05-19
ZA200603356B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
JP5202519B2 (en) (R)-(−)-3- (Carbamoylmethyl) -5-methylhexanoic acid, pregabalin, and synthetic intermediate production method
US7763749B2 (en) Method for the preparation of Pregabalin and salts thereof
US7462738B2 (en) Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
JPH11506098A (en) Method for producing (S) -3- (aminomethyl) -5-methylhexanoic acid
KR20050113292A (en) Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidineacetamide
WO2008062460A2 (en) Crystalline forms of pregabalin
MX2007014781A (en) A process for the dynamic resolution of (substituted) (r) - or (s) -mandelic acid.
HUE031679T2 (en) Process for the manufacture of isavuconazole or ravuconazole
US8273917B2 (en) Method for preparing chiral baclofen
US7026345B2 (en) Resolution of 3-amino alkylnitriles
US5629450A (en) Addition salt of acyl-amino acid and α-aryl amine and process for optical resolution of α-arylamine
US7829702B2 (en) Racemic separation of 2,6-trans-dimethymorpholine
US20140343322A1 (en) Process for preparing levomilnacipran hcl
JP2010513531A (en) Process for the preparation and isolation of individual stereoisomers of 1-amino, 3-substituted phenylcyclopentanecarboxylic esters
JP2014031327A (en) Production method of optically active cis-2-amino-cyclohexane carboxylic acid derivative and precursor of the same
JP2002187873A (en) Method for purifying optically active 1-(trifluromethyl monosubstituted phenyl)ethylamine
JP3005669B2 (en) Method for producing asymmetric fluorinated primary amines
JP2002003453A (en) METHOD FOR PURIFYING OPTICALLY ACTIVE alpha-METHYL- BIS-3,5-(TRIFLUOROMETHYL) BENZYLAMINES
JPS6142A (en) Manufacture of optically active alpha substituted phenylacetic acids
US20220389040A1 (en) An industrial process for resolution of chlocyphos
JPH1045686A (en) Production of optically active 1-phenyl-ethylamines
JPH10279564A (en) Optically active guanidine derivative
JP2004059492A (en) Method for producing optically active alpha-(2-aminophenyl)benzylamine
JPH0755932B2 (en) (R)-or (S) -5-Imidazolylmethyl-3-substituted hydantoin
WO2013098832A2 (en) Novel process for selective isolation and purification of 2-[4-(4-chlorophenyl) cyclohexyl]-3-chloro-1, 4-naphthoquinone and atovaquone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480031857.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174840

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1940/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12006500745

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 546586

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004283151

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2543606

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/03356

Country of ref document: ZA

Ref document number: 2006537456

Country of ref document: JP

Ref document number: 200603356

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004720

Country of ref document: MX

Ref document number: 1020067008176

Country of ref document: KR

Ref document number: 2006114441

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 06040384

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2004769657

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004283151

Country of ref document: AU

Date of ref document: 20041018

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004283151

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200600819

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020067008176

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004769657

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415962

Country of ref document: BR